Efficacy and safety of adjunctive therapy to lamotrigine, lithium, or valproate monotherapy in bipolar depression: a systematic review and meta-analysis of randomized controlled trials

Taku Maruki¹, Tomohiro Utsumi², Masahiro Takeshima³, Yu Fujiwara⁴, Marie Matsui⁵, Yumi Aoki⁵, Hiroyuki Toda⁴, Norio Watanabe⁶, Koichiro Watanabe¹ and Yoshikazu Takaesu¹,7*

Abstract

Background: The efficacy and safety of adjunctive therapy are unclear in bipolar depression. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of second-generation antipsychotic, lamotrigine, lithium, or valproate therapy used in adjunction with lamotrigine, lithium, or valproate monotherapy in bipolar depression. A literature search of major electronic databases was conducted in February 2021, and all articles published until then were eligible. Two researchers independently screened relevant publications, extracted data, and evaluated methodological quality according to the Cochrane criteria.

Results: Five studies met the inclusion criteria. The meta-analysis revealed significant differences in the following outcomes: (i) remission rates from depressive episodes (risk ratio [RR]: 1.23, 95% confidence interval [CI] 1.01–1.50, p = 0.04), (ii) improvement in depressive symptoms (standardized mean difference [SMD]: 0.21, 95% CI 0.09–0.34, p = 0.001), (iii) improvement in quality of life (SMD: 0.22, 95% CI 0.06–0.37, p = 0.005), and (iv) rate of adverse events during the study period (RR: 1.12, 95% CI 1.03–1.22, p = 0.008). There was no significant difference between adjunctive therapy and monotherapy in the emergence of suicide-related behaviors, dropout rate during the study period, or rate of manic switching.

Conclusions: Our results suggest that adjunctive second-generation antipsychotics, lamotrigine, lithium, or valproate increase both the benefits and risks in patients with bipolar depression, although there is no significant difference in severe adverse events. Adjunctive therapy should be provided through shared decision-making while considering the patients’ condition in clinical settings.

Keywords: Antipsychotic drug, Bipolar depression, Lamotrigine, Lithium, Treatment-resistant depression

Background

Compared with manic episodes, bipolar depression imposes a greater burden on patients owing to factors, such as social dysfunction, higher risk of suicide, and longer disease duration (Huxley and Baldessarini 2007; Kupka et al. 2007). Even mild depressive symptoms can cause social dysfunction in patients with bipolar...
depression (Kauer-Sant’Anna et al. 2009). Furthermore, bipolar depression is associated with a lower quality of life (QOL) and poorer cognitive performance (Khafif et al. 2021; Matsuo et al. 2021). Therefore, the improvement of the symptoms of patients with bipolar depression is important for both patients and society. Regarding medications as the first-line treatment of bipolar depression, several treatment guidelines recommend monotherapy with second-generation antipsychotic drugs (SGA), such as lurasidone and quetiapine, as well as with mood stabilizers (MS), such as Lithium (Li) and Lamotrigine (LTG) (National Collaborating Centre for Mental Health (UK) 2014; Fountoulakis et al. 2017; Goodwin et al. 2016; Yatham et al. 2018). However, some patients are resistant to monotherapy with SGA or MS in clinical settings regardless of these recommended treatment guidelines. The International College of Neuropsychopharmacology (CINP) guidelines define these patients as having treatment-resistant bipolar depression and recommend other treatment options for their condition (Fountoulakis et al. 2020). There are a few treatment recommendations, including electroconvulsive therapy (ECT), transcranial magnetic stimulation, and bright light therapy, for patients with treatment-resistant bipolar depression. However, transcranial magnetic stimulation and bright light therapy have not shown any clear evidence (Hett and Marwaha 2020; Takeshima et al. 2020). There is evidence that ECT is an effective treatment option for bipolar depression, but it is difficult to conduct ECT for all patients because of the limited resource of the intervention (Schoeyen et al. 2015). Therefore, it is necessary to develop a treatment strategy for bipolar depression.

Adjunctive therapy is expected to be a candidate treatment strategy for bipolar depression. However, adjunctive therapy can increase the risk of potential adverse effects (Galling et al. 2015). Therefore, the clinical question arises as to whether the benefits of adjunctive therapy outweigh the risks when compared with those of monotherapy in bipolar depression. The results of two recent randomized controlled trials (RCTs) have been inconsistent in addressing this question. One study demonstrated the efficacy of adjunctive therapy in improving depressive symptoms (Loebel et al. 2014), whereas the other did not show a significant difference in the improvement of depressive symptoms between adjunctive combination therapy and monotherapy (Suppes et al. 2016). Additionally, many treatment guidelines do not provide clear evidence for both the efficacy and safety of adjunctive therapy with SGA or MS for bipolar depression although these guidelines mention the efficacy of this therapy (National Collaborating Centre for Mental Health (UK) 2014; Fountoulakis et al. 2017; Yatham et al. 2018). Nonetheless, clinicians are likely to use this adjunctive therapy for bipolar depression with inadequate response to monotherapy, even though the efficacy and safety have not been accurately evaluated (Kim et al. 2021). Consequently, there is a significant need for further evidence supporting the use of adjunctive therapy with SGA or MS for bipolar depression with inadequate response to monotherapy.

Therefore, in this systematic review and meta-analysis, we aimed to clarify the efficacy and safety of adjunctive therapy with SGA or MS for bipolar depression.

Methods

This study was conducted in accordance with the PRISMA recommendations for reporting systematic reviews and meta-analyses (Booth et al. 2012) and was preregistered with PROSPERO (registration number: CRD42021269725) (Liberati et al. 2009) (Additional file 3).

Search strategy

We searched the electronic databases, PubMed (search date: February 16, 2021), Cochrane Central Register of Controlled Trials (CENTRAL; search date: February 16, 2021), and Embase (search date: February 16, 2021), for RCTs, using appropriate subject headings and relevant search terms (e.g., “bipolar disorder” and “randomized controlled trial;” see Additional file 1: Table S1). When necessary, we contacted the authors of specific studies to clarify additional points.

Inclusion criteria

Studies meeting the following criteria were included in the review:

1. RCTs performed at the individual or cluster level. Crossover studies were included if they reported results during the first phase of the study (i.e., before the crossover), as the carry-over effect of the first treatment might affect the subsequent phases.
2. Participants diagnosed with bipolar I or II depression, including mixed features and/or rapid cycling, according to the diagnostic criteria used in the specific study (any recognized diagnostic criteria).
3. Participants not taking antidepressants.
4. Studies in which carbamazepine, Li, LTG, and valproic acid (VPA, including divalprox) were used as the MS.
5. Interventions comprised adjunctive therapy with SGA or MS during baseline treatment with SGA or MS.
6. The control groups comprised patients receiving adjunctive therapy with a placebo during baseline treatment with SGA or MS.
Article selection process
One author (YA) removed duplicates prior to eligibility screening. Subsequently, two groups of screeners, with two authors in each group, were created (Group 1: TM and TU, Group 2: YF and MM). In each group, the two authors independently screened the titles and abstracts of the identified references to exclude irrelevant studies. Subsequently, in each group, the two authors independently evaluated the full texts of these references, and ineligible reports were excluded according to the above criteria. The reasons for exclusion were recorded by the authors in each group. Any disagreement between the screeners was resolved by another author (YT) after thorough and systematic discussions. After identifying eligible studies, the full text of each study was examined.

Outcome measures
The primary outcome measures included the following: (1) remission rate from depressive symptoms; and (2) improvement in depressive symptoms measured with any validated depressive symptoms assessment tool [e.g., Montgomery Åsberg Depression Rating Scale (MADRS)]. The rates of remission from depressive/mixed episodes were calculated by dividing the number of participants who achieved remission in a group by the total number of participants in that group. When dichotomous outcomes were not reported, but baseline mean, endpoint mean, and corresponding standard deviations of the MADRD (or other depressive symptoms assessment tool) were reported, we converted continuous outcome data expressed as mean and standard deviation into the remission rate, based on a validated method (Furukawa et al. 2005).

When depressive symptoms were reported as a “mean±standard error,” we converted the value to “mean±standard deviation.” The secondary outcome measures included the following: (3) improvement in QOL; and (4) rate of adverse events during the study period. We calculated the rate of adverse events during the study period based on the reported adverse events occurring in ≥5% of patients in any group. Other outcome measures included; (5) emergence of suicide-related behaviors; (6) dropout rate for all reasons during the study period; and (7) rate of manic switching.

These outcome measures were assessed at baseline and at the endpoint in the study of less than 12 weeks.

Data extraction, study quality, and risk of bias assessment
Four authors were divided into two groups (Group 1: TM and TU, Group 2: YF and MM) for evaluating the quality of the studies and assessing their risk of bias. The authors in each group carefully and independently extracted the relevant data. Another author (YT) performed checks to ensure the quality and consistency of the assessment. The following variables were extracted from each study: demographics of the participants (e.g., education, employment status, and marital status); diagnostic criteria for bipolar depression; details regarding the participants’ bipolar depression history (type, age of onset, family history, and number of mood episodes); details regarding bipolar depression treatment (e.g., MS, antipsychotics, and antidepressants); concurrent psychiatric disorders; country in which the study was performed; depressive and manic symptoms; and definitions of remission from depressive/mixed episodes and rate of manic switching from depressive or euthymic states, if reported. The following additional variables were also recorded: RCT type, study settings (primary or secondary care), inclusion and exclusion criteria for participant recruitment, contents of the intervention (treatments, timing, and dose), contents of the control group intervention, quality assurance of the intervention, funding source, and number of dropouts from the intervention and control groups. The quality of the included studies was evaluated by the same four authors, divided into the same two groups, using the Cochrane risk of bias assessment tool (Higgins and Green 2011). This assessment evaluates the risk of bias in RCTs in terms of seven domains: (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data, (6) selective outcome reporting, and (7) other sources of bias. The rating for each domain can be “yes” (low risk of bias), “no” (high risk of bias), or “unclear” (unclear risk). Any disagreement was resolved through systematic and thorough discussions with another author (YT).

Statistical analyses
The Cochrane Collaboration Review Manager software (RevMan 5.4) was used for statistical analysis. Continuous outcome data from the intervention and control groups were analyzed using effect sizes [standardized mean differences (SMD)] with 95% confidence intervals (CIs). Dichotomous outcomes were analyzed using risk ratios (RR) with 95% CIs. Random effects models were used in all analyses. Publication bias was evaluated using a funnel plot of the treatment effect against the standard error when at least 10 studies were available (Higgins and Green 2011). Therapeutic effects and adverse events were also assessed. Subgroup analysis was conducted to investigate the sources of heterogeneity. We investigated the difference in effects at each type of combination therapy.
Results

Description of studies included in the review
The initial literature search yielded 3146 unique entries published until February 2021 (PubMed, 941; Embase, 1474; and CENTRAL, 1110). After screening the titles and abstracts of the identified reports, the full-text versions of 96 articles were reviewed. Eighty-seven articles were excluded for various reasons (Additional file 1: Table S2), leaving nine articles. The remaining nine articles (five studies) were included in the qualitative synthesis, and five of these RCTs were included in the quantitative synthesis (Fig. 1) (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Houston et al. 2009; Sachs et al. 2011). The remaining five RCTs investigated the antidepressant effects of adjunctive therapy and monotherapy in treatment-resistant bipolar depression.

Study characteristics
Nine articles, comprising five studies, published between 2009 and 2016 were included in this review (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009, 2011; Houston et al. 2009; Sachs et al. 2011; Citrome et al. 2014;
Rajagopalan et al. 2016; Sajatovic et al. 2016). The sample size ranged from 124 to 356, with a total of 1328 participants (Table 1). Of all the participants, 54.7% were female, and the mean age was 41.9 years. The criteria used for the diagnosis of bipolar depression varied across studies. Three studies used the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (Loebel et al. 2014; Suppes et al. 2016; Houston et al. 2009). Two studies used the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (Loos et al. 2009; Sachs et al. 2011). Four studies defined remission from depressive episodes as a MADRS score of ≤ 12 (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Sachs et al. 2011). Two studies defined remission from depressive episodes as a score of ≤ 12 on the Young Mania Rating Scale (YMRS) and a score of ≤ 8 on 21-item Hamilton Depression Rating Scale (HDRS-21) (Houston et al. 2009). One study defined remission from depressive episodes as a score of ≤ 21 on the Hamilton Depression Rating Scale (HDRS-21) (van der Loos et al. 2009). Four studies excluded patients with psychotic features (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Sachs et al. 2011). One study included 4% of patients with psychotic features in the intervention group and 1% in the control group (Houston et al. 2009).

An MS was used by 100% of the participants as the baseline treatment. None of the studies permitted the use of antidepressants. Three studies did not permit the use of antipsychotics without intervention therapy (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009). Two studies did not describe these details (Loebel et al. 2014; Suppes et al. 2016). The percentage of patients who used other permitted concomitant medications was not reported in all the studies. The details of permitted concomitant medications (e.g., benzodiazepines) are presented in Additional file 2: Table S3.

All the studies were individual RCTs (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Houston et al. 2009; Sachs et al. 2011), which were two-armed and double-blind (participants and assessor) (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Houston et al. 2009; Sachs et al. 2011). They were all conducted at a primary care facility and provided information regarding financial support (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Houston et al. 2009; Sachs et al. 2011).

In the intervention group, the intervention drug was added when a patient with bipolar depression did not respond adequately to baseline treatment. All the studies added treatment with SGA or LTG to baseline treatment with LTG, Li, or VPA. There was no study that used SGA and carbamazepine as the baseline treatment. Two studies added lurasidone (dosage range: 20–120 mg/day) to baseline treatment with Li (serum level range: 3.5–7.8 mg/L).

Table 1 Characteristics of study participants

| Study (year) | Intervention/Control | Age year ± SD | Female n (%) | Type of BD I/II n (%) | Phase of BD | Onset age year ± SD | Rapid cycler n (%) | Taking mood stabilizer n (%) |
|--------------|----------------------|---------------|--------------|----------------------|------------|---------------------|---------------------|----------------------------|
| van der Loos (2009) | Intervention: 64 LTG | 45.2 ± 12.1 | 37/64 (57.8) | I: 43 (67.2) II: 21 (32.8) | MDE ND | 12/64 (18.8) | Li: 64 (100) |
| Control: 60 Placebo | 47.6 ± 11.6 | 30/60 (50.0) | I: 41 (68.3) II: 19 (31.7) | MDE ND | 4/64 (6.7) | Li: 60 (100) |
| Houston (2009) | Intervention: 101 Olanzapine | 38.6 ± 11.2 | 61/101 (60.4) | I: 101 (100) | MD ND | 27/101 (26.7) | VPA: 101 (100) |
| Control: 101 Placebo | 38.5 ± 11.1 | 58/101 (57.4) | I: 101 (100) | MD ND | 22/101 (21.8) | VPA: 101 (100) |
| Sachs (2011) | Intervention: 148 Ziprasidone | 40.4 ± 11.4 | 89/147 (60.5) | I: 148 (100) | MDE ND | ND | Li: 53 (36.3) VPA: 52 (35.6) LTG: 41 (28.1) |
| Control: 150 Placebo | 40.4 ± 11.9 | 91/147 (61.9) | I: 150 (100) | MDE ND | ND | Li: 54 (36.7) VPA: 52 (35.4) LTG: 41 (27.9) |
| Loebel (2014) | Intervention: 183 Lurasidone | 41.0 ± 11.5 | 86/179 (48.0) | I: 183 (100) | MDE 28.1 ± 11.0 ND | Li: 90 (50.3) VPA: 89 (49.7) |
| Control: 165 Placebo | 42.6 ± 11.8 | 76/161 (47.2) | I: 165 (100) | MDE 29.5 ± 10.7 ND | Li: 73 (45.9) VPA: 87 (54.4) |
| Suppes (2016) | Intervention: 180 Lurasidone | 43.1 ± 11.9 | 91/176 (51.7) | I: 180 (100) | MDE 28.8 ± 12.1 32/176 (18.2) | Li: 56 (31.8) VPA: 120 (68.2) |
| Control: 176 Placebo | 44.1 ± 12.0 | 93/166 (56.0) | I: 176 (100) | MDE 29.8 ± 12.8 21/166 (12.7) | Li: 57 (34.3) VPA: 109 (65.7) |

Continuous variable is indicated as mean ± SD. Nominal variable values are indicated as number (%)

BD, bipolar disorder; Li, lithium; LTG, lamotrigine; MDE, major depressive episode; MD, mixed depression; n, number; ND, not described; VPA, valproate, including divalproex; SD, standard deviation
0.6–1.2 mEq/L) or VPA (50–125 μg/mL) (Loebel et al. 2014; Suppes et al. 2016). One study added olanzapine (5–20 mg/day) to baseline treatment with divalproex (75–125 μg/mL) (Houston et al. 2009). One study added ziprasidone (40–160 mg/day) to baseline treatment with Li (0.6–1.2 mEq/L), VPA (50–125 μg/mL), or LTG (100–200 mg/day) (Sachs et al. 2011). One study added LTG (at week 8: 200 mg/day) to baseline treatment with Li (0.6–1.0 mmol/L) (Loos et al. 2009). In the control group, all the studies added a placebo to each baseline treatment.

Risk of bias assessment
The risk of bias evaluation (Fig. 2) revealed the following: four RCTs involved adequate randomization methods (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Sachs et al. 2011); three RCTs reported an adequate allocation concealment procedure (Loebel et al. 2014; Suppes et al. 2016; Sachs et al. 2011); all the RCTs had a low risk of bias in the domain, participant, and personnel blinding (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Houston et al. 2009; Sachs et al. 2011); and one RCT was judged to have an unclear risk of bias in the domain, blinding of outcome assessments (Houston et al. 2009). With regard to incomplete outcome data, three RCTs had a high risk of bias owing to a high dropout rate (Suppes et al. 2016; Houston et al. 2009; Sachs et al. 2011). One study had unclear reporting bias (Sachs et al. 2011).

Treatment outcome assessment
The outcomes are summarized in Table 2. Four studies reported remission rates from depressive/mixed episodes (Loebel et al. 2014; Suppes et al. 2016; Houston et al. 2009; Sachs et al. 2011). The remission rate from depressive episodes was reported in all five studies (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Houston et al. 2009; Sachs et al. 2011). The remission rate from depressive episodes was calculated using depressive symptom scores in only one study (Loes et al. 2009). Improvement in depressive symptoms was reported in all five studies (four studies used MADRS and one study used HDRS-21) (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Houston et al. 2009; Sachs et al. 2011). Three studies evaluated the improvement in QOL using the Quality of Life, Enjoyment, and Satisfaction Questionnaire (Loebel et al. 2014; Suppes et al. 2016; Sachs et al. 2011). Four studies evaluated the rate of adverse events (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Sachs et al. 2011), and one of these studies did not describe the details of the adverse events (Houston et al. 2009). Three studies evaluated the emergence of suicide-related behaviors (Loebel et al. 2014; Suppes et al. 2016; Sachs et al. 2011). All studies evaluated the dropout rate for all reasons during the study period (Loebel et al. 2014; Suppes et al. 2016; Loos et al. 2009; Houston et al. 2009; Sachs et al. 2011). Three studies assessed the manic switch rates during the study period (YMRS = 2 and Clinical Global Impressions Scale-Bipolar Version = 1) (Loebel et al. 2014; Suppes et al.
Table 2  Summary of outcomes

| Study (year)     | Measure for depressive symptoms | Severity of depressive symptoms at baseline: score ± SD | Study duration weeks | Improvement in depressive symptoms score ± SDa | Remission rate from depressive symptoms % |
|------------------|---------------------------------|--------------------------------------------------------|----------------------|---------------------------------------------|------------------------------------------|
|                  |                                 | Intervention 28.25 ± 5.97 28.82 ± 6.24               | 8                    | − 15.38 ± 10.56 − 11.03 ± 10.53 0.024       | 46.9a 30.0a 0.0234                        |
| van der Loos (2009) | MADRS                          | Control 28.82 ± 6.24                                   |                      | − 11.03 ± 10.53                            |                                          |
| Houston (2009)    | HDRS-21                         | Intervention 22.45 ± 4.2 21.87 ± 4.9                  | 6                    | − 9.37 ± 5.50 − 7.69 ± 5.43 0.022           | 31 26 0.437                              |
| Sachs (2011)      | MADRS                          | Control 21.87 ± 4.9                                    |                      | − 7.69 ± 5.43                             |                                          |
| Loebel (2014)     | MADRS                          | Intervention 30.0 ± 5.5 28.8 ± 6.1                    | 6                    | − 13.2 ± 14.4 − 12.9 ± 13.2 0.7921          | 33.1 37.2 0.5029                         |
| Loebel (2014)     | MADRS                          | Control 28.8 ± 6.1                                     |                      | − 12.9 ± 13.2                             |                                          |
| Suppes (2016)     | MADRS                          | Intervention 29.1 ± 4.9 29.1 ± 4.7                    | 6                    | − 11.8 ± 9.54 − 10.4 ± 9.54 0.176           | 34 28 0.227                             |
|                  |                                 | Control 29.1 ± 4.7                                     |                      | − 10.4 ± 9.54                             |                                          |

HDRS-21, 21-item Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; SD, standard deviation

a Calculated using the data in the paper
Attrition was observed in 26.5% of the patients (352/1328).

There were significant differences between the intervention and control groups in the remission rates from depressive/mixed episodes (RR: 1.23, 95% CI 1.01–1.50, p = 0.04; 1297 participants, five studies) (Fig. 3), improvement in depressive symptoms (SMD: 0.21, 95% CI 0.09–0.34, p = 0.001; 1297 participants, five studies) (Fig. 4), improvement in QOL (SMD: 0.22, 95% CI 0.06–0.37, p = 0.005; 874 participants, three studies) (Fig. 5), and rate of adverse events during the study period (RR: 1.12, 95% CI 1.03–1.22, p = 0.008; 988 participants, three studies) (Fig. 6). There was no significant difference between the intervention and control groups
in the emergence of suicide-related behaviors (RR: 1.01, 95% CI 0.65–1.58, p = 0.95; 988 participants, three studies) (Fig. 7), dropout rate for all reasons during the study period (RR: 1.14, 95% CI 0.95–1.36, p = 0.15; 1322 participants, five studies) (Fig. 8), and rate of manic switching (RR: 1.09, 95% CI 0.36–3.27, p = 0.88; 818 participants, three studies) (Fig. 9).

Subgroup analysis revealed that when classified according to each type of combination therapy, there were no significant visually and statistically heterogeneity in remission rates from depressive episodes between SGA + MS vs MS + MS ($\chi^2 = 1.10, p = 0.29, I^2 = 9.5\%$) (Fig. 3). Subgroup analysis revealed that when classified according to each type of combination therapy, there were no significant visually and statistically heterogeneity in the improvement of depressive symptoms between SGA + MS vs MS + MS ($\chi^2 = 1.29, p = 0.26, I^2 = 22.5\%$) (Fig. 4). Subgroup analysis revealed that when classified according to each type of combination therapy, there were no significant visually and statistically heterogeneity in dropout rates between SGA + MS vs MS + MS ($\chi^2 = 0.00, p = 0.98, I^2 = 0\%$) (Fig. 8). Subgroup analysis revealed that when classified according to the individual sources of intervention, there was moderate visually heterogeneity, but there was no statistical difference in manic switch rates between SGA + MS vs MS + MS ($\chi^2 = 1.60, p = 0.21, I^2 = 37.3\%$) (Fig. 9).
Discussion

To the best of our knowledge, this is the first systematic review and meta-analysis to investigate the efficacy and safety of SGA or MS therapy used in adjunction with SGA or MS monotherapy in bipolar depression. The results show that SGA or MS adjunctive therapy is more effective than placebo in bipolar depression with inadequate response to LTG, Li, or VPA monotherapy. However, in terms of safety, the rate of adverse events was higher with adjunctive therapy than with monotherapy.
Previous studies have reviewed the mechanisms of action of many agents used in bipolar disorder (Goldberg 2019). For example, neither Li nor MS exert their effects directly on serotonin receptors, but they may exert their effects on those receptors indirectly. In SGA, the receptor profiles of each SGA vary, but for example, 5-HT7 antagonism, 5-HT1A receptor partial agonism, α2b receptor antagonism, and D2 receptor antagonism might improve bipolar depression in quetiapine, and 5-HT2A antagonism might improve bipolar depression in lurasidone (Goldberg 2019; Yatham et al. 2005). The complementary mechanisms of action of each may be effective in adjunctive therapy.

In terms of efficacy, our analysis showed that adjunctive therapy was significantly more effective in improving remission rates, depressive symptoms, and QOL compared with monotherapy. Our results are consistent with the CINP guideline, recommending adjunctive LTG and SGA, such as clozapine and lurasidone, for treatment-resistant bipolar depression (Fountoulakis et al. 2020). Furthermore, our findings are in line with evidence outlined in several treatment guidelines, which describe the efficacy of adjunctive therapy for bipolar depression with inadequate response to monotherapy (National Collaborating Centre for Mental Health (UK) 2014; Fountoulakis et al. 2017; Yatham et al. 2018). However, the CINP guideline recommend only the use of clozapine, lurasidone, olanzapine, quetiapine, and LTG as adjunctive SGA or MS (Fountoulakis et al. 2020). Similarly, the interventions included in our analysis only involved treatment with lurasidone, olanzapine, ziprasidone, and LTG. Furthermore, the baseline treatment included in our analysis only involved treatment with LTG, Li, and VPA. In light of these findings, although adjunctive SGA and MS may be effective in patients with bipolar depression, who do not respond to MS, the combinations of agents used are probably limited. In addition, considering each of the studies included in this meta-analysis, the study with ziprasidone as an intervention had negative results (Sachs et al. 2011). Except for ziprasidone, all the interventions and baseline medications included in this meta-analysis received relatively high recommendations as monotherapy for the treatment of bipolar depression in many guidelines (National Collaborating Centre for Mental Health (UK) 2014; Fountoulakis et al. 2017; Goodwin et al. xxxx; Yatham et al. 2018; Fountoulakis et al. 2020). This fact suggests that combinations of medications that are highly recommended for bipolar depression as monotherapy may be more effective for bipolar depression. Further studies are needed to identify appropriate combinations among antipsychotics and/or MS.

Regarding safety, a recent network meta-analysis on the efficacy and tolerability of pharmacological monotherapy for acute bipolar depression reported that there were no significant differences in dropout rates for all reasons between patients receiving SGA and MS (apart from aripiprazole) monotherapy and those receiving placebos (Bahji et al. 2020). In line with these results, our meta-analysis also found no significant differences in dropout rates for all reasons between adjunctive therapy and monotherapy, even though dropout rates are usually expected to be higher with adjunctive therapy than with monotherapy. Furthermore, our meta-analysis found no significant differences in the emergence of suicide-related behaviors and rate of manic switching with adjunctive therapy than with monotherapy. Therefore, adjunctive therapy may be considered relatively safe. However, our meta-analysis also showed that adjunctive therapy significantly increased the adverse events compared to monotherapy. Therefore, clinicians should carefully monitor adverse events and consider the risk/benefit of adjunctive therapy in each patient.

We were not able to derive any conclusion regarding the long-term efficacy and safety of adjunctive therapy because there were no long-term RCTs that fulfilled our study criteria. There have been three open-label long-term follow-up studies, all of which are extensions of the studies included in this meta-analysis (Loos et al. 2011; Ketter et al. 2016; Pikalov et al. 2017). Two of the three studies evaluated the efficacy and safety of lurasidone therapy adjunctive to baseline Li or VPA therapy, with follow-up periods of 24 weeks and 2 years, respectively. These two studies reported that the efficacy of adjunctive lurasidone therapy was maintained and that the treatment was safe and tolerable during the study periods (Ketter et al. 2016; Pikalov et al. 2017). Another study evaluating the efficacy and safety of adjunctive LTG therapy to Li monotherapy with a follow-up period of 68 weeks reported that the proportion of responders was larger in the LTG group than in the placebo group throughout the study period (Loos et al. 2011). In addition, this study also reported no differences in the prevalence of any adverse events and occurrence of severe adverse events between LTG and a placebo (Loos et al. 2011). Although the results of these studies support the efficacy and safety of adjunctive therapy for treatment-resistant bipolar depression, the overall long-term efficacy and safety of adjunctive SGA or MS therapy are unclear. Therefore, it might be desirable to use adjunctive combination therapy in the short term if possible.

Our subgroup analysis showed small heterogeneities in remission rates from depressive episodes, in the improvement of depressive symptoms, in dropout rates, and in manic switch rates between SGA+MS vs MS+MS.
However, there was only one study on MS + MS therapy, which would be insufficient to investigate heterogeneity. Future controlled trials are warranted to confirm the efficacy and safety of adjunctive combination therapies for bipolar depression with inadequate response to monotherapy.

This study has several limitations. First, we included only five RCTs with a total of 1328 participants, resulting in relatively low statistical power. Therefore, further RCTs with larger sample sizes are needed to clarify the effectiveness of SGA or MS adjunctive therapy to SGA or MS monotherapy in bipolar depression. Second, the intervention and baseline treatments differed across the studies included in our meta-analysis, which may have led to heterogeneity of individual interventions in our results. In addition, the baseline treatment in the included studies was only MS monotherapy, although quetiapine and lurasidone monotherapy is recommended as the first-line treatment for bipolar depression by many treatment guidelines. Third, there is a difference between the setting of this study and clinical setting in the real world. Although this study showed that adjunctive therapy was more effective than monotherapy for bipolar depression, there were a lot of patients who already took polypharmacy (Frye et al. 2000). One study reported that the patients with bipolar disorder are treated naturally with a mean of 4.1 psychotropic medications during the year (Post et al. 2003). Furthermore, the percentage of monotherapy has decreased from 67 to 31% in the first year of treatment for bipolar disorder (Baldessarini et al. 2008). Therefore, it is difficult to interpret these results into a real-world clinical setting. Fourth, there were problems in combining the different pharmacological interventions, SGA + MS and MS + MS, into one analysis. We attempted a meta-analysis with every SGA/MS combination, resulting in fewer interventions and increased heterogeneity. Finally, this study included only short-term RCTs with a study duration of 6 or 8 weeks. Therefore, the long-term efficacy and safety of adjunctive therapy for bipolar depression remain unclear. Further studies are needed to comprehensively investigate the efficacy and safety of adjunctive SGA or MS therapy to SGA or MS monotherapy in bipolar depression.

Conclusions
Adjunctive SGA or MS therapy could increase the benefits and risks in bipolar depression with inadequate response to LTG, Li, or VPA monotherapy. However, long-term efficacy and safety are unclear. Therefore, adjunctive combination therapy should be provided through shared decision-making, while considering the comorbidities and conditions of patients in clinical settings.
References

Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J Affect Disord. 2020;269:154–84.

Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59:1175–83.

Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev. 2012;1:2.

Citrome L, Ketter TA, Cubicario J, Loebeil A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helpful or harmed. J Affect Disord. 2014;155:20–7.

Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2017;20:180–95.

Fountoulakis KN, Yatham LN, Grunze H, Vieta E, Young AH, Blier P, et al. The CINP guidelines on the definition and evidence-based interventions for treatment-resistant bipolar disorder. Int J Neuropsychopharmacol. 2020;23:230–56.

Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry. 2000;61:9–15.

Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Impeding response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol. 2005;20:49–52.

Gallig B, Garcia MA, Osuchukwu U, Hagi K, Correll CU. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf. 2015;14:1181–99.

Goldberg JF. Complex combination pharmacotherapy for bipolar disorder: knowing when less is more or more is better. Focus. 2019;17:218–31.

Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30:495–533.

Hett D, Marwaha S. Repetitive transcranial magnetic stimulation in the treatment of bipolar disorder. Ther Adv Psychopharmacol. 2020;10:204512520973790.

Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Hoboken: Wiley; 2011.

Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA, Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70:1540–7.

Huxley N, Baldessarini RJ. Disability and its treatment in bipolar disorder patients. Bipolar Disord. 2007;9:183–96.

Kauer-Sant’Anna M, Bond DJ, Lam RW, Yatham LN. Functional outcomes in first-episode patients with bipolar disorder: a prospective study from the Systematic Treatment Optimization Program for Early Mania project. Compr Psychiatry. 2009;50:1–8.

Ketter TA, Sarma K, Silva R, Kroger H, Cubicario J, Loebeil A. Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study. Depress Anxiety. 2016;33:424–34.

Khaffi TC, Belizario GZO, Silva M, Gomes BC, Lafer B. Quality of life and clinical outcomes in bipolar disorder: an 8-year longitudinal study. J Affect Disord. 2021;28:2339–49.

Krupa RK, Althusler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, et al. Three more than days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9:531–5.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.

Loebel A, Cubicario J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:169–77.

Matsuo J, Horii H, Ishida I, Hiraiishi M, Ota M, Hidese S, et al. Performance on the Wechsler Adult Intelligence Scale (WAIS) in Japanese patients with bipolar and major depressive disorders in euthymic and depressed states. Psychiatry Clin Neurosci. 2011;65:128–37.

National Collaborating Centre for Mental Health (UK). Bipolar disorder: the NICE Guideline on the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. London: The British Psychological Society and The Royal College of Psychiatrists; 2014.

Pikalov A, Tsai J, Mao Y, Silva R, Cubicario J, Loebeil A. Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment. Int J Bipolar Disord. 2017;5:9.

Post RM, Denicoff KD, Leverich GS, Althusler LL, Frye MA, Suppes TM, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NWiH life chart method. J Clin Psychiatry. 2003;64:760–9.

Rajagopalan K, Barci ED, Ng-Mak D, Wynick K, Pikalov A, Loebeil A. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC Psychiatry. 2016;16:157.

Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:1413–22.

Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cubicario J, et al. Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. J Clin Psychiatry. 2016;77:1324–31.

Schonen H, Kessler LJ, Andreassen OA, Auestad BH, Bergsholm P, Malt UF, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015;172:41–51.

Suppes T, Kroger H, Pikalov A, Loebeil A. Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. J Psychiatr Res. 2016;78:89–96.

Takeushima M, Utsumi T, Aoki Y, Wang Z, Suzuki M, Okajima I, et al. Efficacy and safety of bright light therapy for manic and depressive symptoms
in patients with bipolar disorder: a systematic review and meta-analysis. Psychiatry Clin Neurosci. 2020;74:247–56.

van der Loos ML, Mulder PG, Hartong EG, Blom MB, Vergouwen AC, de Keyzer HJ, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:223–31.

van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, van Noorden MS, et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord. 2011;13:111–7.

Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(Suppl 5):40–8.

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CNMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.